ArticleOncology letters2016
Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum-Derived microRNAs as Prognostic Biomarkers in Osteosarcoma: A Meta-Analysis.Frontiers in genetics · 2020Pooled it
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.NPJ precision oncology · 2024Review
- The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.Cancers · 2022Review
- Aberrant expression of miR-483-5p in patients with asymptomatic carotid artery stenosis and its predictive value for cerebrovascular event occurrence.Experimental and therapeutic medicine · 2021Article
- Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis.Journal of bone oncology · 2020Review
- Advances in the role of miRNAs in the occurrence and development of osteosarcoma.Open medicine (Warsaw, Poland) · 2020Article
- MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.Cancer cell international · 2020Review
- miR-300/FA2H affects gastric cancer cell proliferation and apoptosis.Open medicine (Warsaw, Poland) · 2020Article
- Retracted Article: Long noncoding RNA DLEU1 promotes cell proliferation and migration of Wilms tumor through the miR-300/HOXC8 axis.RSC advances · 2019Article
- Bioinformatics Analysis Identifies MicroRNAs and Target Genes Associated with Prognosis in Patients with Melanoma.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.Journal of clinical medicine · 2019Review
- Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.Cancers · 2019Review
- Diagnostic and prognostic implications of serum miR-101 in osteosarcoma.Cancer biomarkers : section A of Disease markers · 2018Article
- Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.Oncotarget · 2017Review
- MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis.Oncotarget · 2017Article
- MicroRNAs as a novel class of diagnostic biomarkers for the detection of osteosarcoma: a meta-analysis.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to determine whether microRNA (miR)-300 is a diagnostic and prognostic biomarker in osteosarcoma, the miR-300 levels in serum of 114 osteosarcoma patients and 114 healthy controls were compared, followed by serum analysis of the differences between the pre-operative and post-operative sera of these osteosarcoma patients. It was observed that the concentration levels of miR-300 in the serum of osteosarcoma patients was significantly higher than those in the serum of healthy controls (P<0.01). Furthermore, the concentration levels of miR-300 in the post-operative serum were significantly reduced when compared with the pre-operative serum levels (P<0.001). High miR-300 levels in serum correlated significantly with clinical stage, distant metastasis and poor survival of osteosarcoma patients. Notably, serum miR-300 was an independent prognostic marker for osteosarcoma. In conclusion, our results suggested that serum miR-300 may be a potential and useful noninvasive biomarker for the early detection of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.